MedTrace Logo

MorbiMortality Amelioration in Preeclamptic Primiparas Study. MoMA Pre Prim Study

NCT00763672 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1040

Last updated 2013-03-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether close monitoring of patients with a high sFlt1 plasma level between 25 and 28 weeks of gestation (i.e. at high risk of subsequent preeclampsia) improves maternal and fetal outcomes. The investigator hypothesize that 1/ early screening for preeclampsia by plasmatic sFlt1 will reduce maternal and fetal mortality and morbidity and 2/ a simple urinary PlGF screening will be effective.

Conditions

Interventions

OTHER

Transmission of sFlt-1 results to the investigator

Transmission of sFlt-1 results by the laboratory to the investigator

OTHER

No transmission of the sFlt-1 results to the investigator

The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Principal Investigators

  • Nadia BERKANE, MD · Assistance Publique - Hôpitaux de Paris

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-11-30
Primary Completion
2011-05-31
Completion
2011-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00763672 on ClinicalTrials.gov